Bedtime hypertension treatment improves cardiovascular risk reduction: the Hygia Chronotherapy Trial

COMMENTED

Hypertension

A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial

Lancet.

Schwalm JD, McCready T, Lopez-Jaramillo P, Yusoff K, Attaran A, Lamelas P, Camacho PA, Majid F, Bangdiwala SI, Thabane L, Islam S, McKee M, Yusuf S

doi: 10.1016/S0140-

Cardiovascular Risk and DiseasesHypertension

Impact of Cardiovascular Risk on the Relative Benefit and Harm of Intensive Treatment of Hypertension

J Am Coll Cardiol.

Phillips RA, Xu J, Peterson LE, Arnold RM, Diamond JA, Schussheim AE

doi: 10.1016/j.jacc.2018.01.074.

Myocardial Infarction

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Lancet.

Ridker PM, MacFadyen JG, Everett BM, Libby P, Thuren T, Glynn RJ; CANTOS Trial Group

doi: 10.1016/

Cardiovascular Risk and Diseases

Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial

JAMA Cardiol.

Verma S, Bain SC, Buse JB, Idorn T, Rasmussen S, Ørsted DD, Nauck MA

doi: 10.1001/jamacardio.2019.3080.

Cardiovascular Risk and DiseasesHeart, Artery and Coronary DiseasesHypertension

All Hypertensive Disorders of Pregnancy Increase the Risk of Future Cardiovascular Disease

Hypertension.

Tooher J, Thornton C, Makris A, Ogle R, Korda A, Hennessy A

doi: 10.1161/

Cardiovascular Risk and Diseases

Changing Results-Engage and Activate to Enhance Wellness: A Randomized Clinical Trial to Improve Cardiovascular Risk Management

J Am Heart Assoc.

Iturralde E, Sterling SA, Uratsu CS, Mishra P, Ross TB, Grant RW

doi: 10.1161/JAHA.119.014021.

Hypertension

Benefits and Harms of Antihypertensive Treatment in Low-Risk Patients With Mild Hypertension

JAMA Intern Med.

Sheppard JP, Stevens S, Stevens R, Martin U, Mant J, Hobbs FDR, McManus RJ

doi: 10.1001/jamainternmed.

Cardiovascular Risk and DiseasesHypertension

Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis

JAMA Cardiol.

Bundy JD, Li C, Stuchlik P, Bu X, Kelly TN, Mills KT, He H, Chen J, Whelton PK, He J

doi: 10.1001/

Cardiovascular Risk and DiseasesHypertension

On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults With Isolated Systolic Hypertension

Hypertension.

Yano Y, Rakugi H, Bakris GL, Lloyd-Jones DM, Oparil S, Saruta T, Shimada K, Matsuoka H, Imai Y, Ogihara T

doi: 10.1161/

Related content

A community-based comprehensive intervention to reduce cardiovascular risk in hypertension (HOPE 4): a cluster-randomised controlled trial

Impact of Cardiovascular Risk on the Relative Benefit and Harm of Intensive Treatment of Hypertension

Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomised controlled trial

Occurence of First and Recurrent Major Adverse Cardiovascular Events With Liraglutide Treatment Among Patients With Type 2 Diabetes and High Risk of Cardiovascular Events: A Post Hoc Analysis of a Randomized Clinical Trial

All Hypertensive Disorders of Pregnancy Increase the Risk of Future Cardiovascular Disease

Changing Results-Engage and Activate to Enhance Wellness: A Randomized Clinical Trial to Improve Cardiovascular Risk Management

Benefits and Harms of Antihypertensive Treatment in Low-Risk Patients With Mild Hypertension

Systolic Blood Pressure Reduction and Risk of Cardiovascular Disease and Mortality: A Systematic Review and Network Meta-analysis

On-Treatment Blood Pressure and Cardiovascular Outcomes in Older Adults With Isolated Systolic Hypertension